Market Place
Sourcing Support
Processa Pharmaceuticals Q3 Business Highlights & Results
30 Oct 2024 //
GLOBENEWSWIRE
Processa Doses First NGC-Cap Patient In Breast Cancer Trial
02 Oct 2024 //
GLOBENEWSWIRE
Processa Pharma to Attend Investor and Industry Conferences in September
03 Sep 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
28 Aug 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19 Aug 2024 //
GLOBENEWSWIRE
Myriad Genetics To Report Q2 2024 Results On August 6
30 Jul 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
17 Jul 2024 //
GLOBENEWSWIRE
Processa Announces Positive Efficacy Results from Preliminary Evaluation
11 Jun 2024 //
GLOBENEWSWIRE
Processa To Participate In EF Hutton Global Conference
06 May 2024 //
GLOBENEWSWIRE
Processa Names Dr. Steven Cha SVP Clinical Research
30 Apr 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals NGC-Cap Phase 1b Data At AACR 2024
11 Apr 2024 //
GLOBENEWSWIRE
Processa to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 //
GLOBENEWSWIRE
Processa Pharma to Present Data at the American Association for Cancer Research
25 Mar 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
21 Feb 2024 //
GLOBENEWSWIRE
Processa to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Conference
14 Feb 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
06 Feb 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
26 Jan 2024 //
GLOBENEWSWIRE
Processa Announces Completion of Phase 1b Evaluation of NGC-Cap
25 Jan 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program
19 Jan 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
18 Jan 2024 //
GLOBENEWSWIRE
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
02 Jan 2024 //
GLOBENEWSWIRE
Processa Provides Interim Analysis from Ongoing Phase 1b Trial of Capecitabine
19 Dec 2023 //
GLOBENEWSWIRE
Processa Announces Phase 2 Meeting with FDA for Next Generation Capecitabine
13 Dec 2023 //
GLOBENEWSWIRE
Processa Pharma to Present at the MedInvest Oncology Investor Conference
30 Nov 2023 //
GLOBENEWSWIRE
Processa Pharma Issues Letter to Shareholders Highlighting Corporate Strategy
29 Nov 2023 //
GLOBENEWSWIRE
Processa Mourns the Sudden Passing of Board Member Virgil Thompson
13 Nov 2023 //
GLOBENEWSWIRE
Processa to Present at the 20th Orphan Drugs and Rare Diseases Congress
09 Nov 2023 //
GLOBENEWSWIRE
Processa Announces Formation of Advisory Board with Renowned Key Opinion Leaders
01 Nov 2023 //
GLOBENEWSWIRE
Processa Pharmaceuticals to Present at the ThinkEquity Conference
13 Oct 2023 //
GLOBENEWSWIRE
Processa to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Processa Announces Q3 2021 Results and Provides Corporate Update
11 Nov 2021 //
FIRSTWORDPHARMA
Processa`s Next Gen Capecitabine Inhibits DPD in Phase 1b Interim Analysis
05 Nov 2021 //
GLOBENEWSWIRE
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients
17 Mar 2021 //
GLOBENEWSWIRE
Processa Pharma prices $19.2M public offering; uplisted to Nasdaq
02 Oct 2020 //
SEEKINGALFA
Processa Pharmaceutical Enters Licensing Agreement with Elion Oncology
27 Aug 2020 //
CONTRACTPHARMA
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN
20 Aug 2020 //
GLOBENEWSWIRE
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT
01 Jun 2020 //
GLOBENEWSWIRE
